Drug intelligence / Profile preview

LSI-206

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LSI-206 is a liposomal reformulation of a generic small molecule oncology drug developed by LipoSeuticals. The candidate utilizes the company's proprietary liposomal delivery platform to enhance the delivery and efficacy of an established chemotherapy agent while potentially reducing systemic toxicity. LSI-206 is intended for intravenous administration and is part of a broader pipeline of liposomal reformulations (including LSI-205 and LSI-207) targeting various cancers. The specific active pharmaceutical ingredient (API) for LSI-206 has not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on LSI-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSI-206.

Explore the full profile